

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : C07K 15/28, A61K 39/395 C12N 5/22, G01N 33/53	A1	(11) International Publication Number: WO 91/18928 (43) International Publication Date: 12 December 1991 (12.12.91)
(21) International Application Number: PCT/US91/03508 (22) International Filing Date: 17 May 1991 (17.05.91) (30) Priority data: 530,850 29 May 1990 (29.05.90) US 701,129 16 May 1991 (16.05.91) US (71) Applicants: CEDARS-SINAI MEDICAL CENTER [US/ US]; 8700 Beverly Boulevard, Los Angeles, CA 90048 (US). LOUISIANA STATE UNIVERSITY AND AG- RICULTURAL AND MECHANICAL COLLEGE [US/US]; 433 Bolivar Street, New Orleans, LA 70112-2223 (US). (72) Inventors: HO, David, Da-i ; 6 Iris Lane, Chapaqua, NY 10514 (US). ROBINSON, James, Edmun ; 2703 Camp Street, New Orleans, LA 70130 (US).		(74) Agents: HAAKE, Deborah, L. et al.; 611 West Sixth Street, 34th Floor, Los Angeles, CA 90017 (US). (81) Designated State: JP. Published <i>With international search report.</i> <i>With amended claims and statement.</i>
(54) Title: IMMUNOREAGENTS REACTIVE WITH A CONSERVED EPITOPE OF HUMAN IMMUNODEFICIENCY VIRUS TYPE I (HIV-1) gp120 AND METHODS OF USE		
(57) Abstract The invention features immunoreagents which neutralize the Human Immunodeficiency Virus Type 1 (HIV-1) by binding to a novel conserved epitope of the HIV-1 gp120. These immunoreagents exhibit a broad neutralizing effect upon HIV attachment to host cells, and are therefore useful in the detection, prevention, amelioration and treatment of HIV disease, primarily AIDS (Acquired Immunodeficiency Syndrome) and ARC (AIDS Related Complex). More particularly, the invention relates to novel human monoclonal antibodies selectively reactive to a conserved conformation dependent determinant of the HIV-1 gp120, derivatives thereof, cell lines that produce these antibodies, and the use of the monoclonal antibodies and their derivatives for the detection, prevention, amelioration and treatment of HIV related disease.		

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MN	Mongolia
BE	Belgium	GA	Gabon	MR	Mauritania
BF	Burkina Faso	GB	United Kingdom	MW	Malawi
BG	Bulgaria	GN	Guinea	NL	Netherlands
BJ	Benin	GR	Greece	NO	Norway
BR	Brazil	HU	Hungary	PL	Poland
CA	Canada	IT	Italy	RO	Romania
CF	Central African Republic	JP	Japan	SD	Sudan
CG	Congo	KP	Democratic People's Republic of Korea	SE	Sweden
CH	Switzerland	KR	Republic of Korea	SN	Senegal
CJ	Côte d'Ivoire	LI	Liechtenstein	SU	Soviet Union
CM	Cameroon	LK	Sri Lanka	TD	Chad
CS	Czechoslovakia	LU	Luxembourg	TG	Togo
DE	Germany	MC	Monaco	US	United States of America
DK	Denmark				

DESCRIPTIONImmunoreagents Reactive With a Conserved
Epitope of Human Immunodeficiency Virus
Type I (HIV-1) gp120 and Methods of Use

This application is a continuation-in-part of copending United States application Serial No. 530,850, filed May 29, 1990. The invention disclosed in this application was made, in part, with government support
5 under Grant No.: AI-24030 awarded by the National Institutes of Health (NIH).

1. Technical Field

This invention is in the field of immunotherapy. Specifically, the invention relates to the development of
10 antibodies and derivatives thereof, cell lines that secrete the antibodies, and their method of use in the prevention, detection, amelioration or treatment of HIV disease, primarily AIDS (Acquired Immunodeficiency Syndrome) and ARC (AIDS Related Complex).

15 2. Background Art

Recent scientific inquiry has focused upon an extracellular glycoprotein of Human Immunodeficiency Virus Type 1 (HIV-1), namely gp120. This glycoprotein is believed to play a vital role in attachment of HIV-1 to a
20 host cell, by binding specifically to the host cell's cellular receptor CD4 and therefore important for the development of an AIDS vaccine. However, the gene encoding gp120 is highly variable among different HIV-1 strains, including sequential isolates from the same
25 patient (1-4). The greatest variability has been demonstrated in several hypervariable regions which are flanked by more conserved regions (3, 4).

In response to the AIDS virus, the host immune system will produce antibodies targeted against various antigenic

sites, or determinants, of gp120. Some of those antibodies will have a neutralizing effect and will inhibit HIV infectivity. It is believed that this neutralizing effect is due to the antibodies' ability to interfere with HIV's cellular attachment. It is also believed that this effect may explain in part, the rather long latency period between the initial seroconversion and the onset of clinical symptoms.

Much of our present knowledge about which domains of gp120 are immunogenic has come from studies of antibodies raised in laboratory animals. It was first observed that a variety of animals immunized with purified or recombinant gp120 or gp160 developed strain specific neutralizing antibodies (5-7). Subsequently, polyclonal animal antisera raised to recombinant or synthetic peptides representing the third hypervariable domain (V3) of gp120 (covering amino acid residues 307-330) were found to manifest similar strain specific neutralizing activity. This observation identified the V3 domain as a major target of neutralization, at least in laboratory animals (8,9). The V3 hypervariable region is flanked by conserved cysteine residues which may form a disulfide bond and define a "loop" region containing the largely conserved sequence Gly-Pro-Gly in its center. Synthetic loop region peptides have been found to elicit the production of antibodies that neutralize only virus obtained from isolates from which the synthetic peptide was derived. Hence, the V3 loop induces type-specific neutralizing antibodies; but these antibodies do not account for the broad virus-neutralizing activity detected in the sera of most infected persons.

Several type-specific neutralizing murine monoclonal antibodies have been produced that bind to epitopes within the V3 domain (10-12), allowing precise mapping of these epitopes. Murine monoclonal antibodies have also been generated to epitopes associated with the CD4 binding region near the COOH terminal of gp120 (14-15); but the

extent that this region is also involved in neutralization has not yet been conclusively established. Although the peptide sequence in this region is relatively well conserved, Lasky et al (14) detected minor sequence differences in several virus strains. This finding has raised the possibility that some antigenic variation may also occur within the CD4 binding domain.

Our present knowledge about which epitopes of gp120 stimulate humoral responses in chronically infected humans is much more limited. In contrast to the type-specific neutralizing activity of animal antisera, sera of HIV infected patients generally contain more broadly reactive, group specific neutralizing antibodies (15-17). Such broadly neutralizing antibodies may be directed against a conserved site on gp41, against antibodies specific for gag proteins (31-35), or possibly against conformational epitopes on gp120 (42). Nevertheless, several groups of investigators have also observed that some patient sera manifest distinct patterns of strain-restricted neutralizing activity when tested against a variety of strains (5,6,18,19). Moreover, patient antibodies that have undergone affinity purification to gp120 from one virus strain have been shown to possess type-specific neutralizing activity against that strain (6). These observations suggest that the multiplicity of antibodies commonly detected early in HIV-1 positive patient sera to variable epitopes may mask important later antibody responses to broad neutralization epitopes, which are believed to develop approximately six-twelve months after initial HIV seroconversion. Consequently, the need exists for the development of such agents with broad binding and neutralizing capabilities for the prevention, diagnosis and treatment of HIV and AIDS related infections. The present invention satisfies this need and provides related advantages as well.

The papers cited throughout this application are incorporated herein by reference.

3. Disclosure of the Invention

We have discovered four (4) previously undescribed and unrecognized human monoclonal antibodies which exhibit binding affinity for a specific conserved antigenic determinant of gp120. Tests indicate this binding to be dependent upon the tertiary or non-linear structure of the glycoprotein, and is important for both HIV-1 neutralization and CD4 binding. In addition, and in part because of the unexpected and surprising potency with which HIV infectivity is neutralized by these monoclonal antibodies, we believe the HIV determinant to be located in the CD4 binding region of gp120.

a. Definitions

As used herein, the terms "immunoreagent," "immunoreagent equivalent" and "immunoreagent derivative" refer to antibodies, antibody fragments, antisera, anti-idiotypes, polypeptides or derivatives thereof, whether human, hybrid, chimeric or recombinant, purified or produced by any method, whether conjugated to toxins to enhance immunotoxicity or other molecules to enhance immunogenicity, and the cell lines which produce the antibodies, which bind in an equivalent manner to gp120, have similar neutralization activity, or otherwise mimic this epitope, and their use for the prevention, diagnosis, treatment or amelioration of HIV related disease.

As used herein, references to "gp120 antigen," "gp120 antigenic determinant" and "epitope of HIV-1 gp120," refer to that portion of the HIV-1 virus which is capable of combining with antibodies and derivatives thereof, T cell receptors and immunoreagents which mimic T cell receptors, and which is capable of inducing an immune response.

As used herein, the terms "reactive" or "reactivity" refer to an ability of the immunoreagent to recognize, bind to and/or mimic an antigen, antigenic determinant or epitope.

b. Method of Production

Because epitopes recognized by immunized animals may differ from those that stimulate antibody responses in naturally infected humans, we have produced human monoclonal antibodies (HMabs) that represent immunogenic responses of chronically infected patients to gp120 antigens. This production incidentally has allowed more precise identification and characterization of both conserved and variant gp120 determinants recognized by the human immune system. These IgG HMabs were produced by B cell lines derived by EBV transformation of peripheral blood B lymphocytes obtained from three asymptomatic HIV-1 infected patients. However, these antibodies and derivatives thereof, can also be produced in animals or with the help of hybridoma methods (monoclonal antibodies in mice or monoclonal antibodies in humans) or in yeast, bacteria or mammalian cells by recombinant methods.

In particular, N70-1.5e, N70-1.7B, N70-2.1H and Y76-4.8D bind to a previously undescribed and unrecognized conformation dependent epitope on gp120, and exhibit surprisingly great potency for HIV neutralization. This epitope also appears to be responsible for inducing the broad HIV neutralizing and cellular binding inhibitory activity observed in HIV infected human sera.

Antibodies or equivalent structures, that bind to this site can be used to generate anti-idiotypic antibodies. The anti-idiotypes will share certain three-dimensional features with the original antigen to which our antibodies and like molecules bind. Moreover, the anti-idiotypes immunologically mimic the HIV antigens, as they are readily generated from the claimed antibodies and like-molecules. Furthermore, the anti-idiotypes are relatively non-toxic to humans, and elicit an immune response in the same manner as the corresponding epitopes of the original antigens, yet without the accompanying viral threat to the patient. By challenging a patient's immune system with a judicious mixture of anti-idiotypes,

a broad immune response can be induced to many variants of the HIV virus. This is known in the field of immunotherapy as active immunization, and is an area where this invention could find valuable potential. The
5 antibody or equivalent immunoreagent could be covalently linked to a solid phase matrix for affinity purification, and the purified product, in admixture with an acceptable pharmaceutical excipient, used as an AIDS vaccine.

We specifically disclose human monoclonal antibody
10 N70-1.5e (I5e) as the prototype antibody and the best mode of our invention at this time. However, it is to be understood that future embodiments with superior or more broad N70-1.5e-like characteristics may be discovered or generated, or other embodiments may be utilized without
15 departing from the scope of the invention. In this regard, we also specifically disclose human monoclonal antibodies N70-1.7B, N70-2.1H and Y76-4.8D, generated subsequent to the discovery of N70-1.5e, which in preliminary experiments, appear to have N70-1.5e-like
20 binding and neutralizing activity.

c. Application

The following suggested uses for the present invention are not intended to limit the scope of the invention, but rather provide a small window of
25 understanding to illustrate its broad application and enormous potential.

As such, the antibodies and/or their derivatives could be used therapeutically in several different situations:

- 30 1. the prevention of HIV-1 infection in persons with acute exposure to HIV (e.g. needle sticks);
2. the prevention of vertical transmission to infants from HIV infected mothers;
3. passive immunotherapy of patients with
35 established HIV infection; and

4. active immunotherapy of patients using a mixture of anti-idiotypes or equivalent immunoreagents.

These antibodies and/or their equivalent immunoreagents, in admixture with an acceptable pharmaceutical excipient, could therefore be useful in the development of a vaccine for AIDS, as well as in monitoring the retention of the conformational epitope in HIV-1 vaccines containing all or a portion of gp120.

In addition, these antibodies and/or their equivalent immunoreagents could be used in an immunoassay for diagnosing AIDS in a test sample from a human, and for monitoring antibody responses in AIDS vaccine recipients. The test sample for use in an immunoassay could be any one of whole blood, lymphatic fluid, serum, plasma, semen, saliva, and cerebral spinal fluid; and the presence of the AIDS virus infection could be indicated by the presence of gp120 antigen/immunoreagent complexes in the test sample.

For all such diagnostic, prophylactic and therapeutic uses, the monoclonal antibodies and/or their derivatives as well as other necessary reagents and appropriate devices and accessories may be provided in kit form. The kit can be prepared in a single container, individual bottles, bags, vials or other containers each having an effective amount of the immunoreagent for therapeutic or diagnostic use. This kit can comprise, for example, the immunoreagent in a single container, optionally as a lyophilized plug, and a container of solutions for reconstitution.

These immunoreagents could also be used to further elucidate the structure and function of various other gp120 determinants.

We therefore disclose and claim human monoclonal antibodies N70-1.5e, N70-1.7B, N70-2.H and Y76-4.8D and derivatives thereof, and the cell lines which produce the antibodies, which bind in an equivalent manner to gp120, and have similar neutralization activity, and their use for the prevention, diagnosis, treatment or amelioration

of HIV related disease. However, those skilled in the art will readily appreciate modifications and changes in the procedures, compositions and methods of use set forth without departing from the scope and spirit of the invention. Moreover, other features and advantages of the present invention will become apparent from the following detailed description which illustrates the principles of the invention.

4. Brief Description Of The Drawings

10 The present invention will be described in connection with the accompanying drawings in which:

FIGURE 1 is a Western blot of HMab reactivity with two HIV-1 viral strains, IIIB and J62. The reactivity of four HMabs with strips in both panels is as follows: Lane 1, K24-3b, Lane 2, N70-2.3a, Lane 3 N70-1.5e, Lane 4, N70-1.9b. Lane 5 demonstrates the reactivity of sheep anti-HTLV-IIIB gp120.

FIGURE 2 is a dot blot illustrating the reactivity of four HMabs with purified gp120 of strain J62, non-reduced recombinant LAV gp120, reduced recombinant LAV gp120, and nonreduced, heated LAV gp120.

FIGURE 3 is a graphic representation of ELISA reactivity of K24-3b and N70-2.3a HMabs with Con-A immobilized gp120 from nine strains of HIV-1. Results are shown as the mean optical density (O.D.) reading from triplicate determinations. Standard deviation bars are shown. H72 is the code designation of an HIV-1 antibody positive control serum.

FIGURE 4 is a graphic representation of ELISA reactivity of N70-2.3a, N70-1.5e, and N70-1.9b HMabs with Con-A immobilized gp120 from eight strains of HIV-1. Results are shown as single determinations.

FIGURE 5 illustrates the reactivity of K24-3b and N70-2.3a HMabs with Western blots prepared from eight independent HIV-1 strains. Panel A represents the reactivity of K24-3b; and Panel B represents the

reactivity of N70-2.3a. The different strains are indicated by code numbers at the top of each blot lane; IIIB refers to HTLV-IIIB.

FIGURE 6 represents serologic studies performed with HMAb I5e against various HIV variants alone, or in combination with soluble CD4 (sCD4), dithiothreitol (DTT) and tunicamycin. In particular:

PANEL A represents I5e reactivity with diverse HIV-1 isolates: IIIB, RF, AL, MN and Z84; whereas PC is the positive control serum reacting with IIIB proteins.

PANEL B represents the competition between I5e and sCD4 for binding to gp120/160 of HIV-1.

PANEL C represents that gp120 reduction by DDT eliminates I5e reactivity.

PANEL D represents that I5e reactivity with the envelope protein of HIV-1 is lost when glycosylation is inhibited by tunicamycin.

FIGURE 7 demonstrates I5e neutralization of diverse HIV-1 isolates: -O-, IIIB; -Δ-, RF; ■, Z84; □, AL; ·, MN; ▲, SA3.

FIGURE 8 displays I5e neutralization of nine out of ten primary HIV isolates. Note the variable potency. ·, AC, ·, JRCSF; Δ, JRFL; □, LS; ■, CC; ▲, JM; ▽, RP; ▽, TB; ♦, EP; ♦, LL.

FIGURE 9 illustrates that I5e blocks CD4-gp120 binding more efficaciously than HMAb directed against the epitope described by Lasky et al.

FIGURE 10 provides further proof that the I5e binding site is novel. In particular, Figure 10 shows competition for I5e binding to gp120 by [A] other anti-gp120 MAb's: 9784 (▽; directed against the V3 loop of gp120), G3-536 (·), G3-537 (□), and G3-136 (Δ); and by [B] normal human serum (·) and HIV-1-positive human sera (Δ, ·, ▲, □).

In FIGURE 10A, no competition is observed between I5e and antibodies directed at previously described epitopes (i.e., "loop," NH₂-terminus, and the Lasky site).

FIGURE 10B shows the competitive inhibition of I5e binding by sera obtained from six AIDS patients. Competitive inhibition of I5e occurred with convalescent sera, but not with the sera from acute seroconverters. It is believed that I5e inhibitory antibodies develop approximately six-twelve months after initial HIV seroconversion.

FIGURE 11 is a graphic representation of ELISA reactivity of N70-1.7B and N70-2.1H HMabs with Con-A immobilized gp120 from eleven strains of HIV-1. Results are shown as the mean O.D. from triplicate determinations. Standard deviation bars are shown.

5. Detailed Description

A. Production Of Human Monoclonal Antibodies (HMabs)

The following examples and procedures are provided to illustrate the methods for obtaining antibodies, derivatives thereof, and their use. They are not, however, intended to limit the invention, which extends to the full scope of the appended claims.

20 i. Epstein-Barr Virus Transformation

Peripheral blood mononuclear cells (PBMC) from three adult HIV-1 seropositive male subjects were isolated on Ficoll-Hypaque gradients. PBMC were depleted of CD3 positive T cells using an indirect panning technique (20) in which cells reacting with the OKT3 monoclonal antibody were absorbed to petri dishes coated with F(ab)₂ antibodies to mouse IgG. Non-adherent cells, enriched in B cells, were inoculated with the B95-8 strain of EBV (21) and plated at 10³ or 10⁴ cells per well in ninety-six well tissue culture plates with irradiated human umbilical cord blood lymphocytes (HUCL, 10⁵ cells per well) as feeder cells. Cultures were maintained in RPMI 1640 containing 5% fetal calf serum (FCS) and 1% Nutridoma-HU (Boehringer-Mannheim), a serum substitute of low protein content.

ii. ELISA

Two methods were used to immobilize HIV-1 antigens in wells of ELISA plates for antibody screening. In one system, HIV-1 infected H9 cells were immobilized in
5 Concanavalin-A (Con-A) coated assay wells and then fixed with 1:1 acetone-methanol. The wells were blocked with RPMI-10% FCS for one hour. Fluids from ninety-six well cultures were transferred to wells in the assay plates. After one hour, wells were washed with phosphate buffered
10 saline (PBS) containing 0.1% Triton-X 100 (PBS-Tx) and then reacted with peroxidase-conjugated antibody to human IgG (Protos Labs). Color was developed with 100 μ l tetramethylbenzidine (TMB)-H₂O₂ as substrate. The reaction was stopped by the addition of H₂SO₄ and color was read as
15 Optical Density (O.D.) at 450 nm in a Titertek Multiskan ELISA reader.

The other ELISA method was a novel immunoassay based on the observation that HIV envelope glycoproteins bind via their carbohydrate moieties to Con-A (22). In this
20 system, wells of Immulon-2 assay plates (Dynatech) were coated with 200 μ l/ml Con-A in PBS. The wells were then incubated with 100 μ l of detergent disrupted supernatant fluids from HIV-1 producer cell lines grown for two-three days in serum free RPMI supplemented with 1% Nutridoma-
25 Hu. In the absence of serum components, disrupted viral glycoproteins present in such culture fluids bind to Con-A in amounts sufficient to function as solid phase antigens in a highly sensitive ELISA. Unreacted Con-A binding sites were blocked with RPMI-10% FCS for one hour.
30 Control antigens were similarly prepared from culture fluids of uninfected MT4 cells. Transformed B cell culture fluids were transferred to both antigen coated and control wells of assay plates which were incubated at room temperature for one hour. Binding of antibodies was
35 measured as in the first assay. This ELISA was also used in later experiments to test the reactivity of HMabs with glycoproteins from different virus strains.

iii. HIV Strains

Eleven HIV-1 strains were used in these studies. Strains C39, J62, SA90, SA96, and L86 were isolated in our laboratory from mitogen activated T cells of five asymptomatic HIV-1 infected subjects by co-cultivation with activated normal T cells in medium supplemented with Interleukin-2 (IL-2). Strain SA3 was similarly isolated in our laboratory from a patient with AIDS; strain HiTi (23) was obtained from Robert Garry, Tulane Medical School; strain K3 was obtained from S.R.S. Rangan of the Tulane Delta Primate Center; HTLV-IIIB (24), the prototype HIV-1 strain, was obtained from American Type Culture Collection; HTLV-III_{MM} (25-26), as well as glycosylated recombinant gp120 from HIV-1_{SF2} (27), was obtained from AIDS Research and Reference Reagent Program. Strains C39, J62, SA96, and SA90 were grown in MT4 cells (28); HTLV-IIIB, HTLC-III_{MM}, SA3, HiTi, and K3 were grown in H9 cells. Strain L86, isolated from the B cell donor of one monoclonal antibody (K24-3B), did not replicate in continuous T cell lines and was propagated in mitogen activated cord blood T cells in medium containing one hundred units per ml recombinant IL-2. To prepare antigens for Con-A immobilization, cells infected with each virus strain were grown for two-three days in serum free medium RPMI supplemented with 1% Nutridoma-HU. Clarified fluids were treated with 1% Triton-X and stored in aliquots at -20 °C until use.

iv. Western Blot and Dot Blot Assays

Extracts of $1-2 \times 10^7$ HIV-1 infected cells prepared by solubilizing cells for thirty minutes in 1% Triton-X followed by removal of insoluble material by centrifugation in a microcentrifuge. Samples were mixed 1:1 with sodium dodecyl sulfate (SDS) sample buffer without reducing agents and heated for 5 min at 90°C. Cell lysates of uninfected H9 and MT4 cells were similarly prepared. Samples were fractionated by electrophoresis

in 7.5% sodium dodecyl sulfate-polyacrylamide gels in a BioRad mini-gel apparatus. Proteins were then electrophoretically transferred to a nitrocellulose membrane. Western blot strips were incubated with
5 blocking buffer (1% bovine serum albumin, 0.5% Tween 20, in 0.5 M NaCl, 10mM Tris, pH 8), reacted first with each antibody preparation, and then with alkaline phosphatase-conjugated antibodies to human or sheep IgG, as appropriate. Colored bands were developed using nitroblue
10 tetrazolium and 5-bromo-4-chloro-3-indolyl-phosphate (NBT-BCIP) as substrate. A sheep antiserum to gp120 of HTLV-IIIB, obtained from the AIDS Research and Reference Reagent Program, was used as positive control in detecting gp120/160.

15 For dot blot assays, strips of nitrocellulose were dotted with 1 μ l of baculovirus-produced, recombinant LAV gp120 at 100 μ l/ml and J62 envelope glycoproteins, which were partially purified from detergent treated serum-free culture medium by lentil lectin affinity chromatography
20 (22) and concentrated to 10 μ l/ml. Recombinant gp120 was also dotted after being heated for five minutes at 95°C in the presence or absence 2-mercaptoethanol. Antibody assays on dot blot strips were performed as for Western blots, except a goat antiserum to gp160 of HTLV-IIIB (29)
25 was used as a positive control.

v. Isolation of Antibody Producing B Cell Lines

In the first transformation experiment, EBV exposed-T cell-depleted PBMC from an HIV-1 infected donor were plated at 10³ cells per well in ninety-six well culture
30 plates with irradiated HUCL feeder cells. Only about 50% of the cultures were transformed after four-five weeks of culture. Culture fluids were screened by ELISA for IgG antibodies reacting with fixed, immobilized HIV infected H9 cells. One transformed culture, designated K24-3b, was
35 a stable producer of an antibody, which on further testing reacted by indirect immunofluorescence with both fixed and

unfixed HIV-1 infected cells but not with uninfected cells. Multiple subcultures of K24-3b cells were established at low cell density and all continued to produce antibody. We were unable to definitively clone
5 K24-3b and after about eight months all subcultures ceased to grow; but by that time we accumulated about one liter of antibody containing culture medium. Because the original cells were plated at a relatively low cell density and the incidence of transformation was less than
10 50%, it is likely that the K24-3b cell line was established as a clone.

In the second experiment, EBV exposed-T cell-depleted PBMC from another HIV positive subject were seeded at 10^4 cells/well with irradiated HUCL in two
15 ninety-six well plates. Transformation occurred in 100% of the wells. Culture fluids were screened by ELISA for IgG antibodies reacting with Con-A immobilized viral glycoproteins derived from the J62 strain of HIV-1 grown in MT4 cells in serum free medium. Ten transformed
20 cultures produced IgG antibodies reacting with J62 glycoproteins but not with control antigen. Seven cultures produced antibodies for less than two months. Three cell lines, designated N70-2.3a, N70-1.5e, and N70-1.9b, respectively, were stable antibody producers and
25 were cloned at ten cells per well.

The IgG subclass and light chain type of four of the antibodies was determined by reactivity with murine monoclonal antibodies to the four heavy chain subclasses (Behring Diagnostics) or polyclonal goat antibodies to
30 lambda and kappa light chains in a sandwich ELISA. These four HMabs are of the IgG1 subclass; K24.3b, N70-1.5e, and N70-1.9b contain kappa light chains and N70-2.3a contains lambda light chains. Isotyping of the three more recently produced HMabs, N70-1.7B, N70-2.H and Y76-4.8D has not yet
35 been performed. However, we believe them to be also of the IgG1 subclass because of their binding affinity to gp120.

vi. Characterization of HMAb Specificity by Western Blot and Dot Blot Assays

Figure 1 shows the reactivity of four of the HMabs on Western blots of antigens of two HIV-1 strains, HTLV-IIIB and J62. On blots of HTLV-IIIB (Panel A) three HMabs (K24-3B, N70-2.3a, and N70-1.5e) reacted strongly with a prominent band of approximately 120 kd and with a less intense band of 160 kd. Although N70-1.9b appeared to react weakly with gp120 on this blot (Panel A, lane 4), in other assays it did not react with HTLV-IIIB. On blots prepared from strain J62 (Panel B), all four HMabs showed identical binding to a prominent band at 160 kd below which was a diffuse band extending to approximately 120 kd. This diffuse band pattern is characteristic for this strain. The staining patterns obtained with a polyclonal sheep antibody to gp120 on blots of both strains were identical to that observed with the monoclonals (Panels A and B, lane 5). The HMabs did not react with blots of uninfected MT4 or H9 cells.

While these results appeared to indicate that these four HMabs react with gp120 and its uncleaved cellular precursor, gp160, Zolla-Pazner et al (30) recently presented evidence that bands identified as gp160/120 in some commercially available HIV-1 Western blot strips are multimers of gp41. Therefore, to further confirm that the four HMabs are indeed specific for gp120, we tested their binding on dot blots of recombinant LAV gp120 and lentil lectin purified J62 glycoproteins. As shown in Figure 2, three of the four HMabs (K24-3b, N70-2.3 and N70-1.5e) reacted strongly with recombinant gp120. N70-1.9b did not bind to LAV gp120 but did bind to J62 antigen. The amount of J62 antigen dotted was about ten fold less than the recombinant antigen, explaining the weaker staining observed with this antigen. These results, therefore, indicate that the bands of 120 and 160 kd observed on our Western blots indeed represent gp120/160.

In additional Western blot studies, neither K24-3b nor N70-2.3a reacted with blots prepared from cell lysates heated in sample buffer containing 2-mercaptoethanol, suggesting that the epitopes identified were sensitive to reduction. To further test the effect of reduction on these epitopes, the antibodies were tested on dot blots of recombinant gp120 LAV that were heated at 95°C in the presence or absence of 2-mercaptoethanol. The results shown in Figure 2 demonstrate that K24-3b and N70-1.5e did not bind to reduced antigen, that binding of N70-2.3a to reduced antigen was significantly diminished, and that heating alone only slightly diminished the antigenic activity of these antibodies. As N70-1.9b did not bind to LAV gp120, the effect of reduction on its epitope was not determined in this experiment. We have subsequently tested N70-1.9 on dot blots of reduced and non-reduced J62 glycoproteins and observed no reactivity with reduced antigen. (Unpublished data.) Thus, all four HMabs identify reduction sensitive epitopes.

vii. Analysis of Strain Specificity of HMabs by ELISA

The four HMabs tested previously were also tested by ELISA for reactivity with Con-A immobilized viral glycoproteins from different HIV-1 strains. In one experiment (Figure 3) culture fluids of K24-3b and N70-2.3a, and a HIV-1 positive control serum (H72) were tested on a panel of nine different strains, which included L86, the strain isolated from the B cell donor of K24-3b. Antibody N70-2.3a reacted with all nine strains. Although some differences in binding of this antibody on the panel were observed, generally parallel differences were observed with the positive control serum. Thus, it is likely that the binding levels of both N70-2.3a and the H72 serum provide a relative measure of the amounts of gp120 immobilized from each strain. We have no explanation for the much weaker reactivity of N70-2.3a with the L86 strain compared to the positive serum.

However, L86 was the only strain grown in IL-2 dependent primary T cells, which release less virus than continuous cell lines. Possibly more gp41 than gp120 was immobilized in the L86 virus preparation and antibodies to gp41
5 account for the greater serum reactivity.

By comparison to N70-2.3, the K24-3b monoclonal showed remarkable variability in reactivity with these viruses. This antibody reacted with six of the nine strains but did not bind to strains SA3 or K3, and showed
10 minimal binding to strain SA96. Whereas the reactivity of both N70-2.3a and K24-3b with strains L86 and J62 were very nearly the same, the binding of K24-3b to strains SA90 and C39 was much less than N70-2.3a, the difference being greatest with SA90. These observations have been
15 reproducible in assays performed with different batches of antigens. Smaller differences in binding of these two antibodies were also apparent with strains HiTi and HTLV-III. These differences were not related to antibody concentrations, since preparations of both antibodies used
20 in these assays appeared to saturate available antigenic sites on immobilized antigens; and optical densities obtained with serial dilutions of both antibodies up to 1:32 were very nearly the same (data not shown) when tested against the J62 isolate. This data appears to
25 indicate that N70-2.3a identifies a conserved epitope, while K24-3b identifies a variant epitope which is heterogeneously expressed in this panel of virus strains.

Figure 4 illustrates the results of a similar experiment comparing the reactivities of N70-1.9b with
30 Con-A immobilized glycoproteins derived from eight strains. In this experiment, N70-2.3a served as a positive control. Whereas, both N70-1.5e and N70-2.3a reacted strongly with all eight strains, N70-1.9b reacted only with J62, the strain that was used in screening the
35 original B cell cultures for antibody production. The results indicate that N70-1.5e, like N70-2.3a, reacts with an epitope shared by all strains tested thus far, while

N70-1.9b reacts with a strain-restricted epitope. However, in a subsequent experiment, we found that N70-1.9b, as well as the other three HMabs, reacted strongly by ELISA with Con-A immobilized glycoproteins from two other strains, HTLV-III_{MM}, and HIV-1_{SF2}. These findings, which are presented in Table I below, indicate that the N70-1.9b defined epitope is not as highly strain restricted as the results in Figure 5 initially suggested.

TABLE I

Reactivity of Four HMabs with Con-A Immobilized gp120 of Three HIV-1 Strains

Optical Density with Indicated Strain			
HMab	HTLV-III _{MM}	rgp120/HIV-I	J62
K24-3b	1.870	0.681	1.882
N70-2.3a	2.018	1.149	2.007
N70-1.5e	1.924	1.648	1.781
N70-1.9b	1.710	1.307	1.397

To summarize thus far, our data appear to indicate that N70-2.3a and N70-1.5e both identify a conserved epitope, while K24-3b and N70-1.9b (to a lesser extent) appear to identify a variant epitope heterogeneously expressed in a panel of virus strains. Moreover, all four HMabs identify reduction sensitive epitopes.

viii. Strain Specificity of HMabs by Western Blot Analysis

The strain specificity of two of the four HMabs, K24-3b and N70-2.3a, were also tested on Western blots prepared from the panel of HIV-1 strains identified above. The results, shown in Figure 5, are in agreement with results obtained by ELISA. Antibody N70-2.3a reacted with gp120/160 from all eight strains. Antibody K24-3b reacted with gp120/160 from the same strains it identified by ELISA. Similarly, K24-3b failed to react with SA3 and K3; and its minimal reactivity with strain SA96 was below the

sensitivity of photography. Although N70-1.5e and N70-1.9b have not been similarly tested by Western blots on all viruses, the strain restricted reactivity of N70-1.9b, as observed by ELISA, is corroborated by its failure to react with recombinant LAV gp120 in dot blot assays.

ix. HMab N70-1.5e (I5e), The Prototype And The Best Mode Antibody

We consider the I5e HMab to be the prototype because it was the first antibody discovered having specificity for a conformation dependent epitope involved in gp120-CD4 binding. Since then, we have generated three additional HMabs, N70-1.7B, N70-2.1H and Y76-4.8D, which each have I5e-like characteristics. These three new HMabs are still under investigation; however, preliminary data with respect to their neutralization and binding capacity is presented in Section x. below. In the meantime, the I5e HMab was studied in greater detail, employing routine laboratory procedures. (For lab procedures, see: References 16, 37 and 41.) Our findings in this subsequent series of tests is as follows.

In a radio-immunoprecipitation assay, which results are illustrated in Figure 6A, I5e proved to be reactive with gp120 and/or its precursor gp160 from HIV-1 isolates IIIB, MN and Z84, but not with RF and AL.

I5e was also tested for neutralizing activity against multiple laboratory and primary HIV-1 isolates and shown to have broad neutralizing specificity. As illustrated in Figures 7 and 8, HMab I5e exhibited in vitro neutralization activity against four of five laboratory isolates of HIV and nine of ten primary HIV isolates. More importantly, the efficacy of I5e neutralization of these isolates can be realized by their relatively low ID_{50} and ID_{90} values. In Figure 7, I5e neutralized laboratory isolates IIIB, Z84, MN and SA3 with 90% inhibitory doses (the dose required to inhibit activity by 90%; LD_{90}) of 0.4, 0.6, 3.5, and 12.0 ug, respectively. Isolates RF and

AL were refractory to neutralization by I5e, which is consistent with the immunoprecipitation results in Figure 6. The neutralization assay was performed as described previously (16, 37, 41), with the p24 antigen concentration in the supernatant used as the indicator of virus infection.

Figure 8 demonstrates the neutralizing capacity of I5e against ten primary HIV-1 isolates. As illustrated, six primary strains were efficiently neutralized, with an ID₉₀ of less than 1.5 ug, while more I5e was required to neutralize three other strains, and one isolate was completely resistant. These results attest to the great potency and broad specificity of I5e in neutralizing HIV isolates, and are summarized in tabular form in Table II below.

TABLE II
I5E Neutralization

		ID ₅₀ (ug)	ID ₉₀ (ug)
	<u>Lab Strains:</u>		
20	IIIB	0.15	0.4
	Z34	0.03	0.6
	MN	0.50	3.5
	RF	>20.0	>20
	AL	>20.0	>20
25	SA3	0.10	>10
	<u>Clinical Isolates:</u>		
	AC	0.10	0.60
	JRCSF	0.06	1.50
	JRFL	1.50	10.5
30	LS	0.04	0.40
	CC	0.01	0.50
	JM	>20.0	>20.0
	RP	<0.01	0.07
	TB	15.0	>20.0
35	EP	0.05	0.90
	LL	1.00	10.0

We next examined I5e for its ability to compete with CD4 for gp120/gp160 binding, as this is one potential mechanism for the HIV-1 neutralizing activity. In the experiment shown in Figure 6B, increasing doses of sCD4
5 were added to a metabolically labelled lysate of HIV-1 prior to immunoprecipitation. Soluble CD4 competed with I5e in a dose dependent manner, suggesting that the epitope on gp120 for this human monoclonal antibody may be on the surface, which makes contact with CD4. This
10 observation was confirmed by a quantitative competition enzyme immunoassay, with recombinant gp120 captured indirectly onto solid-phase and sCD4. As shown in Figure 9, I5e blocked gp120 - sCD4 binding in a dose-dependent manner. In fact, it was more potent in doing so than two
15 mouse anti-gp120 monoclonal antibodies, G3-536 and G3-537, previously mapped to the putative CD4-binding site described by Lasky et al. (17). The amount of I5e, G3-536 and G3-537 required to reduce gp120 - sCD4 binding by 50% was 70, 2,500 and 200 ng/ml, respectively. Further
20 epitope classification studies, as illustrated in Figure 10A, indicated that the I5e epitope does not overlap any previously described epitope, including the "loop," the NH₃-terminus and the Lasky site.

Together, these findings suggest that the epitope of
25 I5e is probably not composed of a linear sequence. Instead, the epitope is likely to be conformation or carbohydrate dependent or both. The conformational nature of the I5e epitope was confirmed by the studies shown in Figure 6C. After reduction of a metabolically labeled
30 lysate of HIV-1 by 0.1 M dithiothreitol, the gp120/gp160 reactivity of I5e was lost. Similarly, the importance of glycosylation to I5e - gp120 reactivity was confirmed by the studies shown in Figure 6D, where metabolically
35 labeled HIV-1 lysates were prepared in the absence and presence of tunicamycin. The unglycosylated enveloped precursor polypeptide of 90 kD was not recognized by I5e, perhaps because of alterations in the tertiary structure.

Alternatively, it is possible that an oligosaccharide moiety contributes directly to form a part of the I5e epitope. In any event, these findings suggest that I5e epitope is not localized to previously defined functional domains of gp120 and is likely to be a novel site important in both CD4 binding and antibody neutralization of HIV-1.

Neutralization activity was also observed more broadly across various sera from primary HIV isolates than with lab isolates. Furthermore, as shown in Figure 10B, it was observed that sera from HIV infected patients competitively inhibited I5e binding, whereas sera from acute seroconverters did not. This finding suggests that the I5e binding site may be responsible for inducing the broad neutralizing and binding inhibitory activity observed in convalescent human sera (six to twelve months after initial HIV seroconversion). TABLE III below represents I5e reactivity with a number of HIV isolates.

23

TABLE III

	Peptide Antigen	HIV-1 Isolate	Amino Acid No.	Source	Enzyme Immunoassay	
					O.D.	Results
5	gp120	IIIB	29-511	purified (NIH)	1.212	+
	rgp120	SF2	28-509	recomb., CHO (Chiron)	1.096	+
	rgp120			recomb., CHO (Chiron)	1.162	+
	rgp120			recomb., baculo (Chiron)	0.321	+
	rgp120			recomb., E. coli (Chiron)	0.051	-
10	env2-3	SF2	28-509	recomb., yeast (Chiron)	0.089	-
	PE3	HXB2	1-287	recomb., E. coli (DuPont)	0.107	-
	PB1	HXB2	288-463	recomb., E. coli (Repligen)	0.046	-
	PEnv9	HXB2	464-511*	recomb., E. coli (DuPont)	0.041	-
	C1	HXB2	85-100	synthetic (Tanox)	0.023	-
15	R13	HXB2	174-188	synthetic (Tanox)	0.033	-
	C2-1	HXB2	197-213	synthetic (Tanox)	0.035	-
	C2-2	HXB2	209-223	synthetic (Tanox)	0.025	-
	C2-3	HXB2	219-233	synthetic (Tanox)	0.028	-
	C2-4	HXB2	229-243	synthetic (Tanox)	0.030	-
20	C2-5	HXB2	239-253	synthetic (Tanox)	0.030	-
	C2-6	HXB2	249-263	synthetic (Tanox)	0.027	-
	C2-7	HXB2	259-273	synthetic (Tanox)	0.028	-
	V3-2	HXB2	308-322	synthetic (Tanox)	0.047	-

24

5	C3-1 (T35S)	HXB2	413-447	synthetic (Tanox)	0.031
	R11	HXB2	430-439	synthetic (Tanox)	0.021
	I	Bru	430-439	synthetic (Tanox)	0.022
	II	Bru	432-441	synthetic (Tanox)	0.027
	III	Bru	434-443	synthetic (Tanox)	0.024
10	IV	Bru	436-445	synthetic (Tanox)	0.027
	V	Bru	438-447	synthetic (Tanox)	0.021
	VI	Bru	440-449	synthetic (Tanox)	0.019
	44	Bru	430-449	synthetic (Tanox)	0.030
	P4	HXB2	451-477	synthetic (Tanox)	0.071
-	P3	HXB2	466-477	synthetic (Tanox)	0.029
	P2	HXB2	476-492	synthetic (Tanox)	0.025
	P1	HXB2	489-512	synthetic (Tanox)	0.025
	-	-	-	-	-

x. HMABs N70-1.7B, N70-2.1H And Y76-4.8D

Since the discovery of HMab I5e, we have produced three new HMabs exhibiting I5e-like activity. All three were generated by EBV transformation of B cells. While
 5 N70-1.7B and N70-2.1H were derived from B cells obtained from the same patient from whom I5e was derived, HMab Y76-4.8D was derived from a different patient.

We initiated our examination of these HMabs by testing the strain specificity of HMabs N70-2.1H and N70-
 10 1.7B by ELISA for reactivity with Con-A immobilized viral glycoproteins from eleven different HIV-1 strains. Our results are illustrated in Figure 11 and Table IV. As Figure 11 shows, HMab N70-2.1H demonstrated particularly strong reactivity with all eleven strains in the panel.
 15 HMab N70-1.7B showed similar strong activity, reacting with ten of eleven strains; the MN strain being the only non-reactive strain. In Table IV, the third HMab, Y76-4.8D, was shown to have similar I5e-like behavior; although weaker reactivity was seen with the RF and SF2
 20 strains. However, these results constitute merely preliminary data; whether any of the newly produced antibodies is better than I5e with respect to neutralization remains to be determined by further experimentation.

25

TABLE IV

Comparison of Strain Specificity of HMabs 4.8D and 1.5e

	Virus Strain	OD with Indicated HMab	
		4.8D	1.5e
	J62	1.562	1.857
30	HiTi	1.714	1.962
	IIIB	1.893	2.002
	MN	1.453	2.049
	RF	.717	.568
	SF2	.562	1.714

We next examined the three new HMabs for their ability to compete with each other for the same or overlapping epitopes on gp120. In this experiment, gp120 of HIV-1 strain J62 was immobilized in wells of an Immulon II assay plate (Dynatech Laboratories) which were coated with HMAb N70-1.9b at 10 ug/ml PBS for one hour. The wells were reacted with each unlabeled HMAb (Competing Antibody), and then with either biotinylated N70-2.3a or biotinylated N70-1.5e. The relative amount of bound biotin - labeled antibody was determined by incubating peroxidase - streptavidin (Boehringer-Mannheim) in the wells and developing color using TMB-H₂O₂. Optical density was read at 450 nm.

As shown in Table V, low O.D. readings for the unlabeled antibodies, as compared to the control O.D. for each biotin-HMAb, indicates that an unlabeled HMAb competes for an antigenic site which overlaps the site recognized by labeled antibody. As illustrated, N70-2.3a competes with biotin-2.3a but not with biotin-1.5e. In contrast, N70-1.5e, N70-1.7B, N70-2.1H and Y76-4.8D all have low O.D. readings for biotin-1.5e, indicating that all compete with N70-1.5e.

TABLE V
Competition of HMabs with Biotinylated HMabs 2.3a and 1.5e

25	Competing Antibody	OD with Indicated Labeled HMAb	
		<u>Biotin-2.3</u>	<u>Biotin-1.5e</u>
	2.3a	.115	1.071
	1.5e	1.313	.135
	1.7B	1.496	.432
30	2.1H	1.580	.129
	4.8D	1.209	.455
	None	1.101	1.102

In Figures 6B and 9, we established that I5e recognizes an epitope involved in gp120 - CD4 binding. As

a result, we were interested in determining whether the new HMAb N70-2.1H also recognized an epitope involved in gp120 - CD4 binding. In this experiment, three concentrations of srCD4 (10 ug/ml, 5 ug/ml and 2.5 ug/ml) were incubated with gp120 of HIV-1₆₂ immobilized in Con-A coated wells. HMabs N70-2.3a, N70-1.5e and N70-2.1H were added to the wells and their binding determined using the peroxidase-anti-human IgG system as described previously. As shown in Table VI, srCD4 had no effect on the binding of N70-2.3a. However, srCD4 at all concentrations tested, significantly diminished the binding of both N70-1.5e and N70-2.1H. Hence, it appears that N70-2.1H, like N70-1.5e, also recognizes an epitope involved in gp120 - CD4 binding.

15

TABLE VI

Competition of HMabs with Soluble rCD4

Optical Density with Indicated Concentration
of CD4

	<u>HMAb</u>	<u>10 ug/ml</u>	<u>5 ug/ml</u>	<u>2.5 ug/ml</u>	<u>None</u>
20	2.3A	1.460	1.371	1.386	1.263
	1.5E	.272	.413	.447	1.061
	2.1H	.404	.476	.466	.856

B. Discussion Of Working Examples Of The Preferred Embodiment

25 We disclose the production of six IgG HMabs with specificity for gp120/160 to HIV-1 by B cell lines derived by EBV transformation of peripheral blood B cells obtained from three asymptomatic HIV-1 infected patients. Five HMabs (N70-2.3a, N70-1.5e, N70-1.7B, N70-2.1H and Y76-
30 4.8D) bind to epitopes shared by the majority of strains tested thus far, and therefore, tentatively identify well conserved epitopes. The sixth antibody, (K24-3b), binds to variant epitopes, identifying an epitope that is absent in 2 virus strains and heterogeneously expressed in 9

other strains. Together these results demonstrate the feasibility of using HMAb production by EBV transformed cells to probe human antibody responses to both variant and conserved epitopes of gp120 that are immunogenic in chronically infected hosts.

With regard to the biological activities of the HMABs, preliminary studies have indicated that N70-1.5e has surprisingly potent neutralizing activity against HTLV-IIIIB, even at antibody concentrations as low as 1 μ g/ml. (For neutralization procedures, see reference 37.) However, whether any of the newly generated antibodies has broader or more effective neutralizing capacity than I5e remains to be determined. Of interest is the fact that I5e did not bind to gp120 of the RF and AL strains. As Figure 11 illustrates, N70-2.1H appeared to bind all strains tested, including RF; and could therefore have broader activity if, in further experiments, it proves to neutralize as well as I5e. Similarly, N70-1.7B appeared to bind to RF, but did not bind the MN strain; and could also have potentially broader activity if it neutralizes as well as I5e. Experiments have also shown that these antibodies mediate antibody dependent cell-mediated cytotoxicity (ADCC) against target cells expressing gp120/160.

C. The Deposit

A sample of the N70-1.5e cell line was deposited with the American Type Culture Collection (ATCC) on May 25, 1990 and assigned Accession No. CRL10464. A sample of the N70-2.1H cell line was also deposited with the ATCC on May ____, 1991 and assigned Accession No. _____.

We have deposited a sample of the N70-1.5e cell line, what we consider to be the prototype and our best mode, and a sample of the N70-2.1H cell line with the ATCC in order to afford permanence of the deposit and ready accessibility to the public if a patent is granted. All restrictions on the availability of the deposited N70-

1.5e and N70-2.1H cell lines will be irrevocably removed upon the grant of a patent. Moreover, these cell lines will be available during the pendency of this application, as determined by the Commissioner, pursuant to 37 C.F.R. § 1.15 and 35 U.S.C. § 122. We also acknowledge our duty to replace either or both of the deposits during the required term of deposit, should the ATCC be unable to furnish a sample when requested due to the condition of either or both deposits.

BIBLIOGRAPHY

1. Hahn BM, Gonda MA, Shaw GM, et al: Genomic diversity of the acquired immunodeficiency syndrome virus HTLV-III: different viruses exhibit greatest divergence in their envelope genes. Proc Natl Acad Sci (USA) 1985; 82:4813-4817.
2. Starich BR, Hahn BH, Shaw GM, et al: Identification and characterization of conserved and variable regions in the envelope gene of HTLV-III/LAV, the retroviruses of AIDS. Cell 1986; 45:637-648.
3. Modrow S, Hahn, BH, Shaw GM, et al: Computer assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: predictions of antigenic epitopes in conserved and variable regions. J. Virol 1987; 61:570-578.
4. Hahn BH, Shaw GM, Taylor ME, et al: Genetic variation in HTLV-III/LAV over time in patients with AIDS or at risk for AIDS. Science 1986; 232:1548-1554.
5. Weiss RA, Clapham PR, Cheingsong-Popov R, et al: Variable and conserved neutralization antigens of human immunodeficiency virus. Nature (London) 1986; 324:572-575.
6. Matthews TJ, Langlois AJ, Robey WJ, et al: Restricted neutralization of divergent human T-lymphotropic virus type III isolates by antibodies to the major envelope glycoprotein. Proc Natl Acad Sci (USA) 1986;83:9709-9713.
7. Nara PL, Robey WG, Pyle SW, et al: Purified envelope glycoproteins from human immunodeficiency virus type I variants induce individual, type specific neutralizing antibodies. J Virol 1988; 62:2622-2628.
8. Palker TJ, Clark ME, Langloise AJ, et al: Type-specific neutralization of the human immunodeficiency virus with antibodies to env-encoded synthetic

- peptides. Proc Natl Acad Sci (USA) 1988;85:1932-1936.
9. Rusche JR, Javaherian K, McDanal C, et al: Antibodies that inhibit fusion of human immunodeficiency virus-infected cells bind to a 24 amino acid sequence of the viral envelope, gp120. Proc Natl Acad Sci (USA) 1988; 85:3198-3202.
10. Matsushita S, Robert-Guroff M, Rusche J, et al: Characterization of a human immunodeficiency virus neutralizing monoclonal antibody and mapping of the neutralizing epitope. J. Virol. 1988; 62:2107-2114.
11. Skinner MA, Ting R, Langlois AJ, et al: Characteristics of a neutralizing monoclonal antibody to the HIV envelope glycoprotein. AIDS Research and Human Retroviruses 1988; 4:187-197.
12. Skinner MA, Langlois AJ, McDanal CB, et al: Neutralizing antibodies to an immunodominant envelope sequence do not prevent gp120 binding to CD4. J Virol 1988; 62:4195-4200.
13. Linsley PS, Ledbetter JA, Kinney-Thomas E, and Hu SL: Effects of anti-gp120 monoclonal antibodies on CD4 receptor binding by the env protein of human immunodeficiency virus type 1. J Virol 1988; 62:3695-3702.
14. Lasky LA, Nakamura G, Smith D, et al: Delineation of a region of the human immunodeficiency virus type 1 gp120 glycoprotein critical for interaction with CD4 receptor. Cell 1987; 50:975-985.
15. Dowbenko D, Nakamura G, Fennie C et al: Epitope mapping of the human immunodeficiency virus type 1 gp120 with monoclonal antibodies. J Virol 1988; 62:4703-4711.
16. Ho D, Sarngadharan MG, Hirsch MS et al: Human immunodeficiency virus neutralizing antibodies recognize several conserved domains on the envelope glycoproteins. J Virol. 1987; 61:2024-2028.

17. Robert-Guroff M, Brown M, and Gallo, RC: HTLV-III neutralizing antibodies in patients with AIDS and AIDS-related complex. *Nature* 1985; 316:72-74.
- 18 Harada S, Kobayashi N, Koyanagi Y, and Yamamoto N:
5 Clonal selection of human immunodeficiency virus (HIV): serological differences in the envelope antigens of the cloned viruses and HIV prototypes (HTLV-IIIB, LAV, and ARV). *Virology* 1987; 156:447-451.
- 10 19. Cheng-Mayer C, Homsy J, Evans LA, and Levy JA: Identification of Human immunodeficiency virus subtypes with distinct patterns of sensitivity to serum neutralization. *Proc Natl Acad Sci (USA)* 1988; 85:2815-2819.
- 15 20. Wysocki, LJ and Sato, VL: Depletion of lymphocyte subsets by panning. *Proc Natl Acad Sci (USA)* 1980; 75:2844-2848.
21. Miller, G. and Lipman M: Release of Infectious Epstein-Barr virus by transformed marmoset
20 leukocytes. *Proc Natl Acad Sci (USA)* 1973; 70:190-194.
22. Montagnier L, Clavel F, Krust B, et al: Identification and antigenicity of the major envelope glycoprotein of lymphadenopathy-associated virus.
25 *Virology* 1985; 144:283-289.
23. Rasheed S, Gottlieb AA, and Garry RF: Cell killing by ultraviolet-inactivated human immunodeficiency virus. *Virology* 1986; 154:395-400.
24. Popovic M, Sarngadharan MG, Read E and Gallo RC:
30 Detection, isolation, and continuous production cytopathic retroviruses (HTLV-III) from patients with AIDS and pre-AIDS. *Science* 1984; 224:497-500.
- 25 Gallo RC, Salahuddin SZ, Popovic M, Shearer GM et al: Frequent detection and isolation of cytopathic
35 retroviruses (HTLV-III) from patients with AIDS and at risk for AIDS. *Science* 1984; 224:500-502.

26. Shaw GM, Hahn BH, Arya SK, Groopman JE et al: Molecular characterization of human T cell leukemia (lymphotropic) virus type III in the acquired immunodeficiency syndrome. Science 1984; 226:1165-1170.
27. Levy JA, Hoffman AD, Kramer SM, et al: Isolation of Lymphocytopathic retroviruses from San Francisco patients with AIDS. Science 1984; 225:840-842.
28. Harada S, Koyanagi Y, and Yamamoto N: Infection of HTLV-III/LAV in HTLV-I carrying cells MT-2 and Mt-4 and application in a plaque assay. Science 1985; 229:563-566.
29. Rusche JR, Lynn DL, Robert-Guroff M, et al: Humoral immune response to the entire human immunodeficiency virus envelope glycoprotein made in insect cells. Proc Natl Acad Sci (USA) 1987; 84:6924-6926.
30. Zolla-Pazner S, Gorny MK, and Honnen WJ: Reinterpretation of human immunodeficiency virus western blot patterns. New Engl J Med 1989; 320:1280-1281.
31. Banapour B, Rosenthal K, Rabin L, et al: Characterization and epitope mapping of a human monoclonal antibody reactive with the envelope glycoprotein of human immunodeficiency virus. J Immunol 1987; 139:4027-4033.
32. Sugano S, Masuho Y, Matsumoto Y, et al: Human monoclonal antibody against glycoproteins of human immunodeficiency virus. Biochem and Biophys Res Commun 1988; 155:1105-1112.
33. Morrow WJW, Gaston I, Sooy CD and Levy JA: Human monoclonal antibody directed against gag gene products of the human immunodeficiency virus. J. Immunol. 1988; 140:941-943.
34. Gorny MK, Gianakako V, Sharpe S and Zolla-Pazner S: Generation of Human monoclonal antibodies to human immunodeficiency virus. Proc Natl Acad Sci (USA) 1989; 86:1624-1628.

35. Amadori A, Ciminale V, Calabro ML, et al: Human monoclonal against a gag-coded protein of human immunodeficiency virus produced by a stable EBV-transformed cell clone. AIDS Research and Human Retroviruses 1989; 5:73-78.
- 5 36. Yarchoan R, Redfield RR, and Broder S: Mechanisms of B cell activation in patients with acquired immunodeficiency syndrome and related disorders. J. Clin Invest. 1986; 78:439-447.
- 10 37. Ho DD, Kaplan JC, Rackauskas IE, and Gurney ME: Second conserved domain of gp120 is important to HIV infectivity and antibody neutralization. Science 1988; 239:1021-1023.
- 15 38. Takeda A, Tuason CU and Ennis FA: Antibody-enhanced infection by HIV-1 via Fc receptor-mediated entry. Science 1988; 242:580-583.
- 20 39. Chou MJ, Less TH, Hatsakis A, et al: Antibody responses in early human immunodeficiency virus type 1 infection in hemophiliacs. J Inf Dis. 1988; 157:805-811.
40. Cheng-Mayer C, Seto D, Masatoshi T, and Levy JA: Biologic features of HIV-1 that correlate with virulence in the host. Science 1988; 240:80-82.
- 25 41. Sun NC, Ho DD, Sun CRY, Liou RS, Gordon W, Fund MSC, Li L, Ting RC, Lee TH, Chang NT, Chang TW: Generation and characterization of monoclonal antibodies to the putative CD4-binding domain of HIV-1 gp120. J. Virol., 1989; 63:3579-3585.
- 30 42. Haigwood, NL, Barker, CB, Higgins, KW et al.: Evidence for neutralizing antibodies directed against conformational epitopes on HIV-1 gp120. Vaccines 1990; 90:313-320.

Claims

1. An immunoreagent characterized by specific reactivity with a conserved conformation dependent determinant of HIV-1 gp120.
- 5 2. The immunoreagent of claim 1 characterized by specific reactivity with a conserved conformation dependent and glycosylation dependent determinant of HIV-1 gp120.
- 10 3. The immunoreagent of claim 1 characterized by specific reactivity to a conserved-nonreduced determinant of HIV-1 gp120, but which immunoreagent has no reactivity with the reduced-conserved determinant of HIV-1 gp 120.
- 15 4. The immunoreagent of claim 1 selected from the group consisting of an antibody, an antibody fragment, an anti-idiotypic, a polypeptide, and an antiserum and a derivative thereof.
5. The immunoreagent of claim 4 which is conjugated to a molecule to enhance the biological activity of the immunoreagent.
- 20 6. The immunoreagent of claim 5 which is conjugated to an immunotoxin or an immunogen.
7. An antibody selectively reactive to a conserved conformation dependent determinant of HIV-1 gp 120, and a derivative of such antibody which retains its specificity
25 for that determinant.
8. The antibody of claim 7 selectively reactive to a conserved conformation and glycosylation dependent determinant of HIV-1 gp 120, and a derivative of such antibody which retains its specificity for that
30 determinant.

9. The antibody of claim 7 selectively reactive to a conserved-nonreduced conformation dependent determinant of HIV-1 gp 120, but which has no activity with the reduced-conserved conformation dependent determinant of HIV-1 gp120, and a derivative of such antibody which retains its specificity for that determinant.

10. An antibody secreted by a human derived cell line wherein the antibody is selectively reactive to a conserved conformation dependent determinant of HIV-1 gp 120, and a derivative of such antibody which retains its specificity for that determinant.

11. The antibody of claim 10 secreted by a cell line derived by EBV transformation of B lymphocytes, and a derivative of such antibody which retains its specificity for the conserved conformation dependent determinant of HIV-1 gp120.

12. The antibody of claim 11 wherein the antibody is monoclonal.

13. The human monoclonal antibody of claim 12 secreted by any one of the cell lines N70-1.5e, N70-1.7B, N70-2.1H and Y76-4.8D, and a derivative of such antibody which retains its specificity for the conserved conformation dependent determinant of HIV-1 gp120.

14. A derivative of the monoclonal antibody of claim 13 which is selected from the group consisting of a monoclonal antibody fragment, an anti-idiotypic, a chimeric hybrid antibody, a recombinant hybrid antibody, a polypeptide, an antiserum and a derivative thereof.

15. The monoclonal antibody and derivatives thereof of claim 13 conjugated to a molecule to enhance biological activity.

16. The monoclonal antibody and derivatives thereof of claim 15 conjugated to an immunotoxin or an immunogen.

17. The monoclonal antibody and derivatives thereof of claim 13 wherein the antibody is secreted by the N70-5 1.5e cell line.

18. The monoclonal antibody and derivatives thereof of claim 13 wherein the antibody is secreted by the N70-1.7B cell line.

19. The monoclonal antibody and derivatives thereof of claim 13 wherein the antibody is secreted by the N70-2.1H cell line.

20. The monoclonal antibody and derivatives thereof of claim 13 wherein the antibody is secreted by the Y76-4.8D cell line.

21. The monoclonal antibody derivative of claim 14 which is the fragment F(ab)₂.

22. The monoclonal antibody derivative of claim 14 which is a chimeric hybrid of a murine antibody and a human antibody.

23. The monoclonal antibody derivative of claim 14 which is a recombinant hybrid derived from a bacteria, a yeast or a human cell line.

24. A continuous cell line producing an antibody and derivatives thereof specific for a conserved conformation dependent HIV-1 gp 120 antigenic determinant.

25. The cell line of claim 24 derived by EBV transformation of B cells producing a human monoclonal antibody and derivatives thereof selectively specific for

a conserved conformation dependent HIV-1 gp 120 antigenic determinant.

26. The cell line of claim 25 selected from the N70-1.5e, N70-1.7B, N70-2.1H and Y76-4.8D cell lines.

5 27. The N70-1.5e cell line of claim 26 which is on deposit at the A.T.C.C. and bearing Accession No. CRL10464.

28. The N70-2.1H cell line of claim 26 which is on deposit at the A.T.C.C. and bearing Accession No.
10 _____.

29. A composition for injection purposes comprising a medium containing an immunoreagent selectively reactive to a conserved conformation dependent determinant of HIV-1 gp 120 in admixture with a pharmaceutically acceptable
15 excipient, wherein the immunoreagent is selected from the group consisting of an antibody, an antibody fragment, an anti-idiotypic, a polypeptide and an antiserum.

30. The composition of claim 29 wherein the immunoreagent is conjugated to a molecule to enhance the
20 biological activity of the immunoreagent.

31. The composition of claim 29 wherein the immunoreagent is conjugated to an immunotoxin or an immunogen.

32. An immunoassay method for the detection of an
25 AIDS virus related infection in a human host, which comprises the steps of:

contacting a test sample from a human host containing the conserved conformation dependent HIV-1 gp 120 antigenic determinant with an immunoreagent, the
30 immunoreagent being selected from the group consisting of

an antibody, an antibody fragment, an anti-idiotypic, a polypeptide, an antiserum and a derivative thereof selectively reactive to the conserved conformation dependent HIV-1 gp120 antigenic determinant; and

- 5 determining the presence of the conserved conformation dependent HIV-1 gp120 antigenic determinant in the sample.

33. The immunoassay method of claim 32 which comprises the steps of:

- 10 contacting a test sample from a human host containing the conserved conformation dependent HIV-1 gp 120 antigenic determinant with the immunoreagent, the immunoreagent being selected from the group consisting of an antibody, an antibody fragment, an anti-idiotypic, a
15 polypeptide, an antiserum and a derivative thereof selectively reactive to the conserved conformation dependent HIV-1 gp120 antigenic determinant; and

- determining the presence of the conserved conformation dependent HIV-1 gp120 antigenic determinant
20 in the sample by examining the test sample for the presence of complexes comprising the antigenic determinant and the immunoreagent, the presence thereof indicating the presence of an AIDS virus infection.

34. The method of claim 32 wherein the immunoreagent
25 is conjugated to a label.

35. The method of claim 32 wherein the immunoreagent is conjugated to an immunogen.

36. The method of claim 32 wherein the test sample is selected from the group consisting of whole blood,
30 lymphatic fluid, serum, plasma, semen, saliva, and cerebral spinal fluid.

37. A diagnostic kit comprising:

an immunoreagent capable of binding to a conserved
conformation dependent HIV-1 gp120 antigenic determinant
produced as a result of an infection by the AIDS virus, or
5 a labeled derivative of the immunoreagent, the
immunoreagent being selected from the group consisting of
an antibody, an antibody fragment, an anti-idiotypic, a
polypeptide, an antiserum and a derivative thereof selec
tively reactive with the conserved conformation dependent
10 HIV-1 gp120 antigenic determinant; and
a signal reagent.

38. The kit of claim 37 wherein the immunoreagent is
unlabeled.

AMENDED CLAIMS

[received by the International Bureau
on 13 November 1991 (13.11.91);
original claim 2 cancelled; original claims 1,3-38 amended;
new claims 39-41 added (7 pages)]

1. An immunoreagent characterized by specific reactivity with CD4.
- 5 3. The immunoreagent of claim 1 further characterized by specific reactivity with a conserved conformation dependent and glycosylation dependent determinant of HIV-1 gp120 and having broad HIV neutralizing activity.
- 10 4. The immunoreagent of claim 3 further characterized by specific reactivity to a conserved-nonreduced determinant of HIV-1 gp120, but which said immunoreagent has no reactivity with a reduced-conserved determinant of HIV-1 gp 120.
- 15 5. The immunoreagent of claim 4 selected from the group consisting of an antibody, an antibody fragment, an anti-idiotypic, a polypeptide, and an antiserum and a derivative thereof.
- 20 6. The immunoreagent of claim 5 which is conjugated to a molecule to enhance the biological activity of said immunoreagent.
7. The immunoreagent of claim 6 which is conjugated to an immunotoxin or an immunogen.
- 25 8. An antibody characterized by selective reactivity with CD4.
9. The antibody of claim 8 selectively reactive to a conserved conformation and glycosylation dependent determinant of HIV-1 gp 120, and a derivative of said antibody wherein said antibody and derivative retain both

specificity for said determinant and broad HIV neutralizing activity.

10. The antibody of claim 8 further characterized by
5 selective reactivity to a conserved-nonreduced
conformation dependent and glycosylation dependent
determinant of HIV-1 gp 120, but which has no reactivity
with a reduced-conserved conformation dependent and
glycosylation dependent determinant of HIV-1 gp120, and a
10 derivative of said antibody wherein said antibody and said
derivative retain both specificity for said determinant
and have broad HIV neutralizing activity.

11. An antibody characterized by being secreted by
a cell line derived at least in part from human cells,
15 wherein said antibody is selectively reactive to CD4, said
antibody being reactive to a conserved conformation
dependent and glycosylation dependent determinant of HIV-
1 gp 120, said antibody also having broad HIV neutralizing
activity and a derivative of said antibody which retains
20 both specificity for said determinant and has broad HIV
neutralizing activity.

12. The antibody of claim 11 further characterized
by being secreted by a cell line derived by EBV
transformation of B lymphocytes, and a derivative of said
25 antibody wherein said antibody and said derivative retain
both specificity for said conserved conformation dependent
and glycosylation dependent determinant of HIV-1 gp120 and
have broad HIV neutralizing activity.

13. The antibody of claim 12 wherein said antibody
30 is monoclonal.

14. The human monoclonal antibody of claim 13
secreted by any one of the cell lines N70-1.5e, N70-1.7B,
N70-2.1H and Y76-4.8D, and a derivative of said antibody
5 wherein said antibody and said derivative retain both
specificity for said conserved conformation dependent and
glycosylation dependent determinant of HIV-1 gp120 and
have broad HIV neutralizing activity.

15. A derivative of the monoclonal antibody of claim
10 14 which is selected from the group consisting of a
monoclonal antibody fragment, an anti-idiotypic, a chimeric
hybrid antibody, a recombinant hybrid antibody, a
polypeptide, an antiserum and a derivative thereof.

16. The monoclonal antibody and derivatives thereof
15 of claim 13 conjugated to a molecule to enhance biological
activity.

17. The monoclonal antibody and derivatives thereof
of claim 16 conjugated to an immunotoxin or an immunogen.

18. The monoclonal antibody and derivatives thereof
20 of claim 12 wherein said antibody is secreted by the N70-
1.5e cell line.

19. The monoclonal antibody and derivatives thereof
of claim 12 wherein said antibody is secreted by the N70-
1.7B cell line.

20. The monoclonal antibody and derivatives thereof
25 of claim 12 wherein said antibody is secreted by the N70-
2.1H cell line.

21. The monoclonal antibody and derivatives thereof
of claim 12 wherein said antibody is secreted by the Y76-
30 4.8D cell line.

22. The monoclonal antibody derivative of claim 15 which is the fragment F(ab)₂.

23. The monoclonal antibody derivative of claim 15 which is a chimeric hybrid of a murine antibody and a human antibody.

24. The monoclonal antibody derivative of claim 15 which is a recombinant hybrid derived from a bacteria, a yeast or a human cell line.

25. A continuous cell line characterized by production of an antibody and derivatives thereof wherein said antibody and said derivatives are specific for CD4, being reactive for a conserved conformation dependent and glycosylation dependent HIV-1 gp 120 antigenic determinant and having broad HIV neutralizing activity.

26. The cell line of claim 25 further characterized by being derived by EBV transformation of B cells producing a human monoclonal antibody and derivatives thereof wherein said antibody and derivatives are selectively specific for a conserved conformation dependent and glycosylation dependent HIV-1 gp 120 antigenic determinant and have broad HIV neutralizing activity.

27. The cell line of claim 26 selected from the N70-1.5e, N70-1.7B, N70-2.1H and Y76-4.8D cell lines.

28. The N70-1.5e cell line of claim 25 which is on deposit at the A.T.C.C. and bearing Accession No. CRL10464.

29. The N70-2.1H cell line of claim 25 which is on deposit at the A.T.C.C. and bearing Accession No. CRL10758.

5 30. A composition for injection purposes for the prevention and/or treatment of an HIV associated disease in a host, comprising a medium containing an immunoreagent specific for CD4, being both selectively reactive to a conserved conformation dependent and glycosylation
10 dependent determinant of HIV-1 gp 120 and having broad HIV binding activity, in admixture with a pharmaceutically acceptable excipient, wherein said immunoreagent is selected from the group consisting of an antibody, an antibody fragment, an anti-idiotypic, a polypeptide and an
15 antiserum.

31. The composition of claim 30 wherein said immunoreagent is conjugated to a molecule to enhance the biological activity of said immunoreagent.

32. The composition of claim 30 wherein said
20 immunoreagent is conjugated to an immunotoxin or an immunogen.

33. An immunoassay method for the detection of an HIV associated disease in a host, which comprises the steps of:
25 contacting a test sample from a host suspected of having HIV-1 with an immunoreagent, said immunoreagent being selected from the group consisting of an antibody, an antibody fragment, an anti-idiotypic, a polypeptide, an antiserum and a derivative thereof, wherein said antibody
30 and derivative are specific for CD4, being selectively reactive to said conserved conformation dependent and

glycosylation dependent HIV-1 gp120 antigenic determinant;
and

determining the presence of HIV-1 in the sample.

5 34. The immunoassay method of claim 33 which
comprises the steps of:

 contacting a test sample from a host suspected of
having HIV-1 with said immunoreagent, said immunoreagent
being selected from the group consisting of an antibody,
10 an antibody fragment, an anti-idiotypic, a polypeptide, an
antiserum and a derivative thereof, and wherein said
immunoreagent is specific for CD4, being selectively
reactive to said conserved conformation dependent and
glycosylation dependent HIV-1 gp120 antigenic determinant;
15 and

 determining the presence of HIV-1 in the sample by
examining the test sample for the presence of complexes
comprising said antigenic determinant and said
immunoreagent, the presence thereof indicating the
20 presence of an AIDS virus infection.

35. The method of claim 33 wherein said
immunoreagent is conjugated to a label.

36. The method of claim 33 wherein said
immunoreagent is conjugated to an immunogen.

25 37. The method of claim 33 wherein the test sample
is selected from the group consisting of whole blood,
lymphatic fluid, serum, plasma, semen, saliva, and
cerebral spinal fluid.

38. A diagnostic kit comprising:

- an immunoreagent capable of binding to CD4, having specific reactivity to a conserved conformation dependent and glycosylation dependent HIV-1 gp120 antigenic determinant, said immunoreagent being selected from the group consisting of an antibody, an antibody fragment, an anti-idiotypic, a polypeptide, an antiserum and a derivative thereof selectively reactive with said conserved conformation dependent and glycosylation dependent HIV-1 gp120 antigenic determinant;
a label for said immunoreagent or said derivative thereof; and
a signal reagent.

39. The kit of claim 38 wherein said immunoreagent or said derivative thereof is unlabeled.

40. A method for the prevention and treatment of an HIV associated disease in a host by administering to said host an effective amount of a pharmaceutical composition comprising an immunoreagent and/or a derivative thereof selectively reactive to CD4, having specific reactivity to a conserved conformation dependent and glycosylation dependent determinant of HIV-1 gp120 and having broad HIV neutralizing activity.

41. The method of claim 40 wherein said pharmaceutical composition may be administered orally or by injection.

STATEMENT UNDER ARTICLE 19(1)

Support for the foregoing amendments can be found in the specification as illustrated below.

On page 4, lines 5-12;

On page 21, lines 26-27; 31-38;

On page 6, lines 30-35; and

On page 7, lines 1-29.

The claims, as amended, more particularly define the invention by making specific reference to "an immunoreagent characterized by specific reactivity with CD4, said immunoreagent being reactive with a conserved conformation dependent and glycosylation dependent determinant of HIV-1 gp120 and having broad HIV neutralizing activity." The claims as amended also recite "a method for the prevention and/or treatment of an HIV associated disease in a host" by administering "an effective amount of a pharmaceutical composition comprising" the immunoreagent described above and/or a derivative thereof.

As the Examiner has acknowledged, the following references provide background information for the general state of the art, and do not teach or suggest the subject invention:

1. Journal of Virology, 63(9):3579-3585 (1989);
2. Cell, 50:975-985 (1987); and
3. Science, 229:1202-1207 (1985).

The three references cited below also provide general background information for the state of the art. They also do not teach or suggest immunoreagents which specifically bind CD4 and display specific reactivity with a conserved conformation dependent, glycosylation dependent and reduction sensitive determinant.

1. Biotechnology, 5:940-946 (1987) discloses the general production of unrefined monoclonal antibodies to HIV gp120;
2. Biochemical and Biophysical Research Communications, 155(3):1105-1112 (1988) which also discloses the general production of unrefined monoclonal antibodies to HIV gp120;

3. Clinical Chem., 27(11):1797-1806 (1981) is a review article discussing the general use of monoclonal antibodies in clinical immunology; and
4. Vaccines, 90:313-320 (1989) discloses a group of undefined antibodies with undefined specificity.

As can be seen, none of the references cited in the International Search Report teach or suggest, either alone or in combination, the immunoreagents of the present invention which specifically bind CD4 as demonstrated by their specific reactivity with a conserved conformation dependent, glycosylation dependent and reduction sensitive determinant.

Claims 1 and 3-41 are therefore novel and not rendered obvious by any one of or combination of the references cited above. As such, claims 1 and 3-41 are believed to be in condition for allowance, which allowance is earnestly solicited.

1/11




FIG. 1

2/11

K24-3b	N70-2.3a	N70-1.9b	N70-1.5c	COAT ANTI-gp160	
●	●	•	●	●	gp 120 J62
●	●		●	●	rgp 120 LAV
	•			●	rgp 120 REDUCED
•	•		•	●	rgp 120 HEATED

FIG. 2.

3/11




FIG. 3.

SUBSTITUTE SHEET

4/11




FIG. 4.

SUBSTITUTE SHEET

5/11




FIG. 5.

SUBSTITUTE SHEET

6/11




FIG. 6.

7/11





FIG 7

SUBSTITUTE SHEET

8/11

FIG. 8.



9/11





FIG. 9.

SUBSTITUTE SHEET


10/11

FIG. 10



11/11

FIG. 11.



SUBSTITUTE SHEET

INTERNATIONAL SEARCH REPORT

International Application No. PCT/US91/03508

I. CLASSIFICATION OF SUBJECT MATTER (If several classification symbols apply, indicate all) ³		
According to International Patent Classification (IPC) or to both National Classification and IPC IPC(5): C07K 15/28; A61K 39/395; C12N 5/22; G01N 33/53 U.S. CL: 530/387, 388, 389; 424/85.8, 85.91; 435/240.27, 7.22		
II. FIELDS SEARCHED		
Minimum Documentation Searched ⁴		
Classification System	Classification Symbols	
US. CL:	530/387, 388, 389; 435/240.27, 7.22; 424/85.8, 85.91	
Documentation Searched other than Minimum Documentation to the Extent that such Documents are Included in the Fields Searched ⁵		
Databases: STN International (File CA, File Biosis); Automated Patent Systems		
III. DOCUMENTS CONSIDERED TO BE RELEVANT ¹⁴		
Category ⁶	Citation of Document, ¹⁶ with indication, where appropriate, of the relevant passages ¹⁷	Relevant to Claim No. ¹⁸
X Y	Vaccines 90. Modern Approaches to New Vaccines including prevention of AIDS; Seventh Meeting, September 1989, issued 1990, Haigwood et al., "Evidence for Neutralizing Antibodies Directed against Conformational Epitopes of HIV 1 GP120", Haigwood et al. pp 313-320, see entire document.	1,3,4,7,9 5,6,10-12, 24,25,29-38
Y	Biotechnology, vol. 5, issued September 1987, Fong et al "Monoclonal Antibodies that Neutralize HIV-IVIRIONS and inhibit SYNCYTIUM Formation by infected cells", Fong et al. pp 940-946, see especially page 942.	1,3,4-7,24, 29-38
A	Journal of Virology, vol. 63, No. 9, issued September 1989, Sun et al, "Generation and Characterization of Monoclonal Antibodies to the Putative CD4-binding Domain of Human Immunodeficiency Virus type 1 gp120," pp 3579-3585, see entire document.	
<p>¹⁵ Special categories of cited documents:</p> <p>"A" document defining the general state of the art which is not considered to be of particular relevance</p> <p>"E" earlier document but published on or after the international filing date</p> <p>"L" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)</p> <p>"O" document referring to an oral disclosure, use, exhibition or other means</p> <p>"P" document published prior to the international filing date but later than the priority date claimed</p> <p>"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention</p> <p>"X" document of particular relevance: the claimed invention cannot be considered novel or cannot be considered to involve an inventive step</p> <p>"Y" document of particular relevance: the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art.</p> <p>"&" document member of the same patent family</p>		
IV. CERTIFICATION		
Date of the Actual Completion of the International Search ²	Date of Mailing of this International Search Report ²	
19 August 1991	17 SEP 1991	
International Searching Authority ¹	Signature of Authorized Officer ²⁰	
ISA/US	Paula Hutzel	

FURTHER INFORMATION CONTINUED FROM THE SECOND SHEET

A	Cell, vol. 50, issued September 1987, Laskey et al, "Delineation of a Region of the Human Immunodeficiency Virus Type 1 gp120 Glycoprotein Critical for Interaction with the CD4 receptor," pp 975-985, see entire document.	
Y	Biochemical and Biophysical Research Communications, vol. 155, No. 3, issued 30 September 1988 Sugano et al "Human Monoclonal Antibody against Glycoproteins of Human Immunodeficiency Virus", pp. 1105-1112, see page 1106.	10-12, 24, 25

V. ☐ OBSERVATIONS WHERE CERTAIN CLAIMS WERE FOUND UNSEARCHABLE¹

This international search report has not been established in respect of certain claims under Article 17(2) (a) for the following reasons:

1. ☐ Claim numbers because they relate to subject matter not required to be searched by this Authority, namely:

2. ☐ Claim numbers because they relate to parts of the international application that do not comply with the prescribed requirements to such an extent that no meaningful international search can be carried out¹, specifically:

3. ☐ Claim numbers because they are dependent claims not drafted in accordance with the second and third sentences of PCT Rule 6.4(a).

VI. ☐ OBSERVATIONS WHERE UNITY OF INVENTION IS LACKING²

This international Searching Authority found multiple inventions in this international application as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this international search report covers all searchable claims of the international application.

2. ☐ As only some of the required additional search fees were timely paid by the applicant, this international search report covers only those claims of the international application for which fees were paid, specifically claims:

3. ☐ No required additional search fees were timely paid by the applicant. Consequently, this international search report is restricted to the invention first mentioned in the claims; it is covered by claim numbers:

4. ☐ As all searchable claims could be searched without effort justifying an additional fee, the International Searching Authority did not invite payment of any additional fee.

Remark on Protest

☐ The additional search fees were accompanied by applicant's protest.

☐ No protest accompanied the payment of additional search fees.

Attachment Form PCT/IPEA/210

- Y Clin. Chem., vol. 27 No. 11, issued 1981 5,6,30-38
Sevier et al. "Monoclonal Antibodies in
Clinical Immunology", pp.
1797-1806, see especially pages 1800-1801.
- A Science, vol 229, issued 20 September 1985,
Morrison, "Transfectomas Provide Novel
Chimeric Antibodies", pp. 1202-1207,
see entire document.